drugset / Trial / NCT00586443
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
Phase 1
Completed
56 enrolled
Herbert Hurwitz, MD
Amgen · collabGenentech, Inc. · collabNovartis · collab
NaSingle-groupOpen-label
Summary
Targeting molecular pathways of tumor growth has become a major focus of anti-cancer treatments. This study aims to investigate the toxicity, pharmacokinetics, and preliminary efficacy of the triplet combination of bevacizumab, RAD001, and panitumumab in patients with refractory solid tumors. This open-labeled, non-randomized phase I trial of bevacizumab, everolimus and panitumumab is designed to assess the safety, tolerability and efficacy of this combination in adult patients with advanced solid tumors.
Timeline
- Start
- 2007-11
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Panitumumab | Monoclonal antibody | 3.6 mg/kg | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | 4.8 mg/kg | Intravenous |
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | Intravenous |